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Abstract. Autologous fat is considered the ideal material for 
soft-tissue augmentation in plastic and reconstructive surgery. 
The primary drawback of autologous fat grafting is the high 
resorption rate. The isolation of mesenchymal stem cells 
from adipose tissue inevitably led to research focusing on 
the study of combined transplantation of autologous fat and 
adipose derived stem cells (ADSCs) and introduced the theory 
of ʻcell‑assisted lipotransfer .ʼ Transplantation of ADSCs is a 
promising strategy, due to the high proliferative capacity of 
stem cells, their potential to induce paracrine signalling and 
ability to differentiate into adipocytes and vascular cells. 
The current study examined the literature for clinical and 
experimental studies on cell-assisted lipotransfer to assess 
the efficacy of this novel technique when compared with 
traditional fat grafting. A total of 30 studies were included 
in the present review. The current study demonstrates that 
cell‑assisted lipotransfer has improved efficacy compared with 
conventional fat grafting. Despite relatively positive outcomes, 
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Traditional fat transplantation (fat grafting) is a well-estab-
lished technique and one of the standard approaches to 
soft-tissue reconstruction. Due to the abundance and natural 
properties of fat, fat grafting remains a popular procedure for 
augmentation and reconstruction in aesthetic and reconstruc-
tive surgery (1). However, fat tissue is intolerant to hypoxia 
and ischaemia, which may cause fat resorption in the recipient 
areas. The resulting volume reduction and long-term unpre-
dictability are acknowledged as drawbacks of fat grafting and 
both have been subjects of study since lipotransfer was popu-
larised (2,3). Previous studies have investigated the effect of fat 
grafting enrichment with adipose derived stem/stromal cells 
(ADSCs), indicating that the technique results in increased fat 
graft survival when compared with traditional fat grafting (4). 
The aim of the present study is to explain the basic science of 
ADSC-assisted lipotransfer and to present the experimental 
and clinical data regarding stem cell enhanced fat grafting 
(the where, how and why) outcomes published thus far by 
conducting a review on previous literature.
A literature-based study was conducted using the Pubmed 
(www.ncbi.nlm.nih.gov/pubmed) and Cochrane (www.
cochranelibrary.com) database, from the introduction of the 
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cell-assisted lipotransfer (CAL) technique in January 2008 
to November 2016. Only original studies written in English 
and full text articles were included. Full text articles were 
then cross-referenced. The following search terms were used: 
ʻMesenchymal stem cellsʼ OR ʻMesenchymal stromal cellsʼ 
OR ʻadipose stem cellsʼ OR ʻprocessed lipoaspirate cellsʼ OR 
ʻpre‑adipocytesʼ OR ʻstromal vascular stem cellsʼ OR ʻCell 
assisted fat transfer OR lipotransfer OR lipofilling .ʼ
2. Lipofilling: Advantages and limitations
Autologous fat transplantation (AFT) has been performed 
since the 1890 s and interest in this technique continues to 
increase (5). It is an advantageous reconstructive procedure 
commonly used to treat burns, trauma, lipodystrophies, 
rejuvenation and post tumour excisions (1,6). The advantage 
of easy and abundant harvesting of ubiquitous adipose tissue 
by a minimally invasive procedure explains its popularity 
and rapidly increasing number of clinical applications in 
reconstructive surgery. However, optimal outcomes are yet 
to be achieved, primarily due to graft reabsorption negatively 
impacting the procedure. The resorption rate ranges from 
25 to 80% (7-11). Unpredictability and low survival rates due 
to partial graft necrosis are the most important drawbacks; 
therefore it is important to investigate how to optimize fat 
graft survival (2).
A number of studies have attempted to explain the 
lack of graft persistence and the reasons behind the poor 
outcomes (11,12). It has been demonstrated that inadequate 
vascularisation is a potential cause of fat transplant tissue 
loss and that revascularization of autologous fat transplants 
occurs after 48 h (11). This 48 h delay appears to critically 
impair the survival of the fat cells, which subsequently 
undergo degenerative changes, including cellular destruc-
tion. Following cell destruction and acute necrosis, oily cysts, 
calcification and connective tissue formation develop, and the 
fat gradually becomes absorbed (2). Studies suggest that the 
success of autologous fat grafting depends on the vascularity 
of the recipient site and early and abundant neovasculariza-
tion, potentially explaining why a considerable number of 
mature adipocytes undergo apoptosis during the initial days 
of ischaemia following transplantation (2,3). The fat grafts 
appear to rely on the delivery of nutrients by diffusion until 
neovascularisation and angiogenesis are complete (11,13,14). 
In support of this, studies have indicated that inadequate, 
thicker fat grafts undergo relatively more resorption (15-17). 
According to Coleman et al (16), neoangiogenesis of the 
graft and consequently successful fat grafting may only 
be achieved when small amounts of fat tissue are placed 
in multiple tunnels. A previous study investigated how the 
quality of the graft and graft harvesting factors affect the 
outcome and graft survival rate (18). Mechanical disruption 
reduces the number of mature adipocytes to 30% and adipose 
tissue progenitors to 50%, indicating that any mechanical or 
chemical insult that damages the fragile architecture of fat 
tissue may contribute to partial fat necrosis (19). The congre-
gation of ADSCs around the blood vessels may also explain 
why lipoaspiration alone, which spares large vessels, results 
in poor adipose tissue progenitors in fat grafting and poor 
take of the graft (20).
3. Mesenchymal stromal/stem cells
Mesenchymal stromal/stem cells (MSCs) are multi-potent 
adult stem cells originally identified in bone marrow (21-23). 
Stromal cells are characterised by their ability to differentiate 
into multiple lineages including adipocytes, as well as osteo-
blasts, chondrocytes and myocytes (24).
Since the discovery of MSCs in the 1960s their therapeutic 
potentials have been broadly studied. Bone marrow has been 
extensively studied as an MSC source for tissue engineering 
and regenerative medicine, and was considered for a number 
of years to be the major derivation source (21,25). However 
MSCs have been isolated from almost every tissue in the 
body including adipose tissue, peripheral blood, umbilical 
cord blood, dermis and amniotic fluid, and the field of tissue 
engineering is rapidly advancing (25-28).
ADSCs are a promising population of MSCs identified 
within adipose tissue in 2001 (24) and represent a promising 
alternative to bone marrow-derived MSCs for use in cell-based 
musculoskeletal tissue-engineering strategies (25,26). 
Adipose tissue is a favourable source of stem cells as it can be 
extracted by liposuction in large amounts with minor donor 
site morbidity (29). Typical isolation procedures for ADSCs 
involve mechanical dissociation or enzymatic collagenase 
digestion of the lipoaspirated tissue and subsequent centrifuga-
tion to obtain the component cellular fractions; a high density 
of stromal-vascular fraction (SVF) is produced. The SVF 
contains a highly heterogeneous cell population, including 
endothelial cells, endothelial progenitor cells (EPC), pericytes, 
preadipocytes, fibroblasts, blood‑derived cells and vascular 
smooth muscle cells, in addition to the potential ADSCs (29). 
ADSCs are present as a minor fraction within the SVF and 
may be used directly as a source of ADSCs.
Alternatively, ADSCs may be separated from SVF and 
expanded in vitro culture by adhesion on plastic dishes (30,31). 
The isolation of ADSCs from the SVF is a simple, uncompli-
cated in vitro procedure. In general, cell isolation protocols 
include collagenase-digestion of lipoaspirate or minced 
adipose tissue followed by density gradient centrifugation of 
the enzyme-digested tissue. Stem cell yields are greater from 
adipose tissue than from other stem cell sources (32). As many as 
1x107 ADSCs may routinely be isolated from 300 ml of lipoaspi-
rate, following ex vivo culture, with a yield of 5,000 fibroblast 
colony-forming units per g of adipose tissue, which is 5x the 
estimate of the ADSC yield from bone marrow (33,34).
4. ADSC enhanced fat grafting: Basic science
ADSC populations have angiogenic and neovasculogenic 
properties, explaining why they are therapeutically attractive 
and advantageous to use as seeding cells for regenerative medi-
cine (35-38). Thus, the potential for using autologous ADSCs to 
optimise fat transplantation has become the focus of research 
as the CAL technique promises long lasting results (39). CAL 
is a technique of fat grafting enhancement that essentially 
either adds ex vivo expanded ADSCs to aspirated fat or supple-
ments the fat graft with the SVF cellular suspension, which 
is rich in progenitor cells (ADSC and EPC). This technique 
converts a poor ADSC lipoaspirate to a relatively rich ADSC 
lipoaspirate. This effect of high-level enrichment with ADSC 
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is considered to be due to cellular differentiation and/or para-
crine signalling. In vitro and in vivo studies have demonstrated 
that under apoptotic and degenerative conditions, ADSCs 
divide, migrate and differentiate into adipocytes or vascular 
cells as compensation for the changes occurring during the 
remodelling process (40-44). However, the initial perception 
that engrafted ADSCs possess the ability to differentiate in 
order to replace injured adipocytes, endothelial cells and 
osteoblasts has been gradually replaced; more recent studies 
support that, in order to augment recovery of perfusion under 
ischaemia, ADSCs release soluble mediators in a paracrine 
fashion (45,46). It has been suggested that these mediators 
and angiogenic factors and not the ADSCs themselves may 
be primarily responsible for the trophic, regenerative and 
anti‑inflammatory effects exhibited when ADSCs are in isch-
aemic hypoxic tissue (45). Through the expression of trophic 
factors and immune-modulatory mediators, including vascular 
endothelial growth factor and insulin-like growth factor-1, 
increased angiogenesis, capillary density and subsequently 
graft survival is promoted (46-52). Although both mechanisms 
have been supported by a number of in vitro and clinical 
studies, the science behind CAL is still under investigation and 
remains controversial, as it is still not clear whether this angio-
genetic effect promoted by engrafted ADSCs is as a result of 
bona fide transdifferentiation, or whether this positive effect 
described is arising from an alteration of the tissue microen-
vironment (45). The frequency with which the implanted cells 
undergo adipogenesis remains unclear.
Elucidating the exact fate of the implanted ADSCs and 
determining the optimal cell load for human use are notable 
topics for future research.
5. SVF vs. ex vivo expanded ADSCs
There are different strategies for enriching fat grafts with 
ADSCs (53,54). The first strategy is to isolate SVF from the fat 
and apply it to the recipient site. The SVF introduces stem cells 
and their angiogenic growth factors that subsequently promote 
successful vascularization, graft survival and volume retention. 
Another strategy is the tissue engineering approach. In this 
technique, the adipose derived stem cells are induced to differ-
entiate into mature adipocytes. Growth factors are responsible 
for stimulating the differentiation and are therefore optimally 
delivered in vivo. Tissue engineering techniques may also 
utilize a scaffold system for cell delivery composed of natural 
or synthetic materials, or as a hydrogel. One of the few random-
ized controlled studies on CAL comparing conventional fat 
grafting to ex vivo expanded ADSC-enriched CAL concludes 
that the latter is a feasible and safe alternative that exerts a 
significant and substantial effect (55). However, the enzymatic 
isolation of ADSCs remains a major drawback as long as the 
ex vivo expansion of ADSCs is not practical for application in 
principalities with strict Food and Drug Administration regu-
lations. By contrast, SVF is a mixed cell population including 
ADSCs, which does not require the aid of enzymatic digestion, 
but is disadvantaged by a markedly reduced yield of ADSCs 
compared with ex vivo culturing. Results, however indicate 
that the SVF technique is significantly superior to traditional 
fat grafting, increasing the popularity of the SVF technique in 
clinical practice (29,53-56).
6. Experimental and clinical trials with ADSC‑assisted 
fat grafting
The search of publications completed for the current study 
yielded 15 murine (Table I) (48,52,57-69) and 19 human 
(Table II) (30,53-55,70-84) studies that assessed the effect of 
fat graft enrichment with freshly isolated ADSCs (SVF) or 
ex vivo cultured ADSCs. A total of 24 of the studies compared 
SVF assisted lipotransfer to traditional lipotransfer (control), 
10 compared ex vivo expanded ADSC-enriched fat grafting to 
controls and one animal study compared both. Of the in-human 
studies, 6 were clinical trials, 7 were prospective studies, 
4 were retrospective cohort studies and 2 were case reports. 
An overview of the retrieved studies is provided in Tables I 
and II. In the studies reviewed, the potential improvement 
of cell enriched lipofilling compared with conventional lipo-
filling was assessed primarily by considering two important 
parameters: The quality of the fat graft and the degree of fat 
survival, to elucidate whether CAL was superior to traditional 
lipotransfer; or resorption following transplantation, which 
is the primary disadvantage of the fat grafting technique. In 
the majority of studies the degree of resorption was clini-
cally assessed whereas certain studies used less subjective 
imaging techniques, such as mammography, magnetic 
resonance imaging (MRI) and computed tomography (CT) 
volumetry and three-dimensional imaging. MRI volumetry is 
considered an exact and reproducible imaging technique (85) 
applied for qualitative and quantitative follow-up assessments 
following the grafting of autologous fat to the breast (86,87). 
Three-dimensional imaging is theoretically very exact but 
when measurements are performed in human breasts, volume 
deviation amounts to 60% (88). The quality of graft was 
assessed by the histological appearance in the animal studies 
and by the radiographic appearance in the human studies. The 
animal studies have also sought to investigate the fate of the 
expanded ASDC in the graft by tracking cells.
In the animal studies (n=15) cell assisted lipotransfer was 
compared with traditional fat grafting. Part of the lipoaspirate 
was used to extract the SVF, which was either used directly as a 
source of ADSCs or used for ex vivo expansion of the ADSCs. 
The majority of animal studies (n=11) investigated immuno-
suppressed mice (severe combined immunodeficiency (SCID) 
or nude mice) and only three investigated rabbits (59,60,69). 
Nude mice are the most commonly used murine model for 
xenografting.
The longest follow-up duration was 9 months (48). 
Outcomes were evaluated following extraction of the trans-
planted fat grafts by volume measurement and histological 
studies assessing fat resorption, inflammation, necrosis, 
vascularization and angiogenesis. Fat graft was obtained by 
liposuction of human fat (lipoaspiration of female donors) in 
seven studies, liposuction of inguinal fat in a study on rabbits 
and lipectomy of the inguinal fat in the other seven animal 
studies.
In animal studies, the evidence that enriching fat grafts 
with ADSCs increases volume over time is strong. All studies 
demonstrated a considerable reduction of fat resorption in CAL 
compared with fat grafting alone. Matsumoto et al (52) in 2006 
was the first to describe the strategy of CAL, a technique that 
creates a stem-cell rich fat graft. The ADSC-enriched human 
MOUSTAKI et al:  APPLICATION OF ADSCs IN FAT GRAFTING: BASIC SCIENCE AND LITERATURE REVIEW2418
aspirated fat was transplanted subcutaneously into SCID mice 
resulting in a ~35% increase in average superior survival and 
more prominent microvasculature genesis when compared with 
traditional fat grafting. However, the short follow up period 
Table II. Human studies. 
Study, year N Cell type Follow-up time (months) Study design Evidence level (Refs.)
Rigotti, 2007 20 SVF 30  Case series IV (53)
Yoshimura, 2008 40 SVF <42  Retrospective cohort IV (30)
Yoshimura, 2008 6 SVF 9-13  Prospective cohort III (70)
Yoshimura, 2010 15 SVF <18  Case series IV (71)
Yoshimura, 2008 2 SVF 12  Case report V (72)
Asano, 2010 26 ADSC Unknown Case series IV (54)
Kamakura, 2010 20 SVF 9  Single-arm clinical trial III (73)
Tiryaki, 2011 29 SVF <36  Case series IV (74)
Sterodimas, 2011 20 SVF <18  Randomized clinical trial III (75)
Wang, 2012 18 SVF <6  Case series IV (76)
Perez-Cano, 2012 67 SVF <12  Single-arm clinical trial III (77)
Castro-Govea, 2012 1 SVF <12  Case report V (78)
Li, 2013 38 SVF 6  Retrospective cohort IV (84)
Peltoniemi, 2013 18 SVF <6  Clinical trial III (79)
Tanikawa, 2013 14 SVF <12  Randomized clinical trial II (80)
Kølle, 2013 20 ADSC 4  Randomized clinical trial II (55)
Wang, 2015 12 SVF <6  Case series IV (81)
Domenis, 2015 20 ADSC <12  Prospective cohort IV (82)
Jung, 2015 5 SVF <12  Prospective cohort IV (83)
Evidence levels were used based on the hierarchical system of classifying evidence (85) as follows: I, high-quality prospective cohort study 
with adequate power or systematic review of these studies; II, lesser quality prospective cohort, retrospective cohort study, untreated controls 
from a randomised control trial, or systematic review of these studies; III, case-control study or systematic review of these studies; IV, case 
series; V, expert opinion; case report or clinical example; or evidence based on physiology, bench research, or ʻfirst principlesʼ. N, number of 
patients; SVF, stromal vascular fraction; ASC, adipose-derived stem cells; <, up to.
Table I. Murine studies.
Study, year Donor Recipient Cell type Follow-up (Refs.)
Matsumoto, 2006 Human SCID Mice SVF 4 weeks (52)
Moseley, 2006 Mice SCID Mice SVF/ASC 6 months (57)
Lu, 2009 Human SCID Mice ADSC 6 months (58)
Zhu, 2010 Mice B6129SF1/J Mice ADSC 6 and 9 months (48)
He, 2012 Rabbits Rabbits SVF 3 months (59)
Piccino, 2013 Rabbit New Zealand Rabbits ADSC 3 months (60)
Dong, 2013 Human Nude Mice SVF 2 weeks (61)
Derby, 2013 GFP+mice Nude Mice ADSC 8 weeks (62)
Fu, 2013 GFP+mice BALB/c Nude Mice SVF 56 days (63)
Kakudo, 2013 Human BALB/cAJcl-nu/nu Mice ADSC 5 months (64)
Zhou, 2014 Rats Nude Mice SVF 63 days (65)
Garza, 2015 Human Nude (Crl:NU-Foxn1nu CD-1) Mice ADSC 7 weeks (66)
Jiang, 2015 Human CD-1 Nude Mice ADSC 12 weeks (67)
Paik, 2015 Human Crl:NU-foxn1nu Mice SVF 8 weeks (68)
Ni, 2015 Rabbits Rabbits SVF 3 months (69)
SCID, severe combined immunodeficiency; SVF, stromal vascular fraction; ADSC, adipose‑derived stem cells; GFP, green fluorescence 
protein; CD, caesarian derived; Crl, charles river laboratories; NU, nude.
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was a significant limitation of the study (52). Zhu et al (48) in 
2010 Lu et al (58) in 2009 studied ADSC-assisted lipotransfer 
in mice 9 and 6 months post transfer, respectively. These 
studies demonstrated not only a higher survival rate of the fat 
mass compared with lipotransfer alone but proved that ADSCs 
contributed to vessel formation by direct incorporation into 
endothelial cells and the vessel wall of the neovascular capil-
laries, by marking the transplanted ADSCs with DiI prior to 
transplantation. In 2013, He et al (59) compared SVF enriched 
fat grafting to traditional fat grafting in rabbits and 3 months 
later the retention rate of the former had significantly improved. 
Also in 2013, Piccinno et al (60) published the results of an 
animal study on rabbits comparing ADSC assisted lipotransfer 
to traditional lipotransfer 9 months following transplantation. 
This was the first study where defined numbers of ADSCs 
were introduced into an autologous animal model to challenge 
the therapeutic potential of ASDCs and confirmed, once again, 
that ADSCs assisted fat transfer to generate a protective effect, 
reducing fat necrosis and increasing vasculogenesis (60). A 
major drawback in this study, and indeed every study inves-
tigating tissue engineering using small animal models, is the 
limited body fat obtainable in rabbits and the possible impact 
this may have on the quantity of ASDCs. Dong et al (61) used 
nude mice to demonstrate that ADSCs were the only popula-
tion of SVF cells that survived the ischaemia of fat grafting, 
therefore the immunoregulatory function of SVF cells may be 
beneficial to adipose transplantation.
The 19 human clinical studies involved a total of 321 
CAL procedures (30,53-55,70-84). Only seven studies yielded 
level II or III (high validity) evidence based on the hierarchical 
system of classifying evidence (85), whereas 12 (including the 
majority of human studies) yielded level IV or V (low validity) 
evidence.
The fat graft was supplemented with the cellular suspen-
sion (SVF) or ADSCs prior to transplantation. The majority 
of studies were on breast reconstruction and augmentation, 
followed by congenital, traumatic, disease related and iatro-
genic (radiation-induced) soft tissue defects (30,53,54,70,71,
73,75-81,83).
Patients were typically followed up for 6 to 12 months. The 
longest follow-up duration was 42 months (30). Outcomes were 
typically based on clinical examination, subjective volume 
estimation, imaging and patient/physician satisfaction (n=8). 
However, in the majority of studies more objective evaluative 
methods, including CT/MRI volumetry and mammography 
were also employed (n=11).
In 2007, Rigotti et al (53) presented a marked improvement 
in the first human study on 19 patients with radiation‑induced 
soft tissue defects who underwent CAL. This may be 
considered the first example of regenerating therapies where 
the regenerative properties of the ASDCs were utilized to 
successfully treat tissue damage. A member of the same 
research team who first described cell‑assisted lipotransfer 
technique (52), two years later published preliminary results 
when CAL had been used in two important fields of interest 
in reconstructive surgery: Breast augmentation and facial 
lipoatrophy. The results demonstrated the effectiveness of this 
novel technique in fat graft survival rates with favourable and 
uncomplicated aesthetic outcomes (30,70-72). Furthermore, 
in 2010 the Yoshimura group studied CAL as a safe and 
efficient alternative option to implant based cosmetic breast 
enhancement (54). However, the team's conclusions in both 
studies regarding the superiority of CAL were not supported 
due to two serious drawbacks: Absence of a control group and 
formal quantitative measurements (72). More reliable evidence 
was published in 2011 with the first in‑human prospective 
randomised trial comparing the SVF CAL with the traditional 
method in patients with facial defects (75). Follow-up assess-
ments, six months after a single session demonstrated that 
patient satisfaction was significantly higher compared with 
non-CAL patients, although at 18 months that difference was 
not statistically significant. Similar satisfactory outcomes were 
demonstrated in breast augmentation although the resorp-
tion of SVF enriched fat graft remains unclear (81). In 2013, 
Li et al (84) favoured SVF supplementation in fat grafting 
over traditional fat grafting, demonstrating an enhanced 
clinical improvement compared with fat grafting alone (64.8 
vs. 46.4%). However, Peltoniemi et al (79) performed the first 
comparative prospective study and raised doubts regarding the 
advantage of using stem cell enrichment in cosmetic fat trans-
plantation to the breast. The results of this study suggested that 
no differences in the ADSC phenotype were observed when 
comparing ADSC-enriched lipoaspirate with non enriched 
lipoaspirate; thus suggesting that a more specific study on 
ADSC presence and function in the two lipoaspirates may add 
crucial information (79).
Despite a small number of studies exhibiting no differ-
ence, the majority of human studies clearly demonstrated 
a significant advantage over the non‑CAL fat grafting tech-
nique; however the results were still questionable due to a lack 
of strong evidence. In 2013, the first two in‑human randomised 
controlled trials were published. Tanikawa et al (80) performed 
a randomised blinded clinical trial in patients with craniofacial 
microsomia that compared fat grafting with and without SVF 
supplementation by clinical examination and CT volumetry. 
Although the size of the study groups was relatively small, the 
methodology quality was high and outcomes suggest there is 
a statistically significant difference in fat volume survival at 
6 months (88% in CAL vs. 54% in non CAL). The second study 
was completed by Kølle et al (55) and was the second blinded 
randomised controlled study investigating CAL in humans. 
The strength of this study is that it was the first controlled clin-
ical trial where graft specimens were histologically assessed 
4 months post-transplantation. Traditional fat grafting was 
compared with CAL using autologous culture-expanded 
ADSCs. The significantly higher residual volume of 81% for 
the ADSCs CAL group vs. 16% in the non-CAL group was 
encouraging with respect to the use of this technique in tissue 
augmentation.
7. Optimal cell population
Of the studies included, three used different dosages of cells in 
order to identify the optimal cell population. Kakudo et al (64) 
in 2013 compared ADSC-enriched fat grafting in 3 different 
concentrations to assess traditional fat grafting and identified 
that 3x105 cells/ml is the optimal ASDC concentration.
Paik et al (68) in 2015 used that same xenografting murine 
model (nude mouse) to try and determine the optimal SVF 
cell concentration. Results demonstrated a dose-dependence 
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in the number of SVF cells that may be added to a fat graft to 
enhance retention by comparing fat grafts with and without 
SVF supplementation. Notably, this study observed that the 
maximum graft survival retention was a concentration of 
10,000 SVF cells per 200 µl fat.
Ni et al (69) performed a study that compared different 
mixtures of fat particles with various proportions of SVF and 
identified that 3:1 is the optimal fat particle-to-SVF ratio, 
exhibiting the greatest weight maintenance. The two latter 
studies suggest that there may be a minimum requirement for 
the amount of cells administered in order to achieve a benefi-
cial effect.
8. Discussion
These preliminary studies suggest that ADSCs may improve 
the retention and volume-restoring capabilities of transplanted 
fat. The majority of animal studies used ex vivo expanded 
ADSC‑assisted lipotransfer and demonstrated a significant 
improvement in graft survival and the normal histological 
appearance of the transplanted tissue (48,57,58,60,62,64,66,67). 
By contrast, in human studies, where fat grafts were typically 
enriched with a freshly isolated SVF containing a mixed cell 
population that includes a minor fraction of ADSCs, the reported 
results were not always substantially improved, compared with 
those obtained with traditional lipofilling (70-72). To the best 
of our knowledge, all clinical studies on CAL to date have not 
used a control group to objectively compare the CAL technique 
to conventional lipografting and in many clinical studies, the 
survival evaluation of the transplanted fat was based on subjec-
tive analysis of images and clinical assessment. This may 
introduce a potential source of observer or interpretation bias, 
which has the potential to affect the reliability of the results. 
When radiological evaluation techniques were used to allow 
comparison, the observer bias was eliminated by providing 
more objective data. A recent human study on cosmetic facial 
contouring, comparing traditional to SVF-enriched fat grafting 
demonstrated a significant increase of fat survival with SVF. 
The survival rate however, was only 65% for the SVF-enriched 
grafts vs. 46% for the control grafts (84). Therefore, based 
on the hypothesis that enrichment with ADSCs increases fat 
graft viability, the use of ex vivo expanded ADSC-enriched 
fat grafts in a similar way is expected to lead to far more reli-
able and predictable results than those achieved by the minor 
fraction of ADSCs observed in SVF and without the need for 
overcorrection. Undeniably, the high residual volume of >80% 
in a previous human randomised controlled clinical trial (68) 
is encouraging with respect to the potential use of enriched fat 
grafts in reconstructive surgery following ex vivo expansion of 
collagenase-processed ADSCs used for CAL.
Notably, to achieve these favourable results, the fat graft had 
to be supplemented with ex vivo cultured ADSCs to ~2,000x 
the normal physiological level (55) based on the murine studies 
of Lu et al (58) and Zhu et al (48), where ASDC-concen-
trations were increased 1,250 and 6,250x, respectively, by 
ASDC ex vivo expansion. In both studies, ASDC enrichment 
improved fat graft survival (Table I). However, the optimal 
ADSC concentration of fat grafts has not been extensively 
studied and a consensus on the enrichment technique is still 
lacking. Matsumoto et al (52) also identified an improvement 
in graft survival using ASDCs enriched by a factor of 5, but 
the long-term effect remains unknown, as the duration of the 
study was only 4 weeks. Matsumoto et al (52) also demon-
strated that the concentration of ASDCs in lipoaspirate is only 
half that in excised adipose tissue. Therefore, for comparison 
in cell-assisted lipotransfer, the lipoaspirate is required to 
be 4x the desired volume just to double physiological ASDC 
concentration in the fat graft. However, fat graft enrichment 
with ASDCs without previous expansion limits the increase 
to a factor of 2-5, which is potentially inadequate to exert a 
dynamic effect on graft survival (4). Paik et al (68) in 2015 
demonstrated a dose dependence in the number of SVF cells 
that may be added to a fat graft to enhance retention and 
revealed that grafts receiving 10,000 SVF cells per 200 µl 
of fat had the optimal volume retention. In contrast with 
these conclusions, Sterodimas et al (75) suggested that CAL 
provides a substantial amount of ASDCs without cell culturing. 
Determining the optimal cell load for human use and relating 
ADSC subpopulation analysis to clinical outcomes remains a 
challenge and requires further research.
Overall, evidence supports that ASDC augmented fat 
grafts are successful and may lead to superior volume survival. 
However, the technique has limitations: Ex vivo expansion of 
ADSCs to a high concentration is not practical for application. 
It also takes longer to process fat for CAL and the cost is higher 
when compared with traditional fat grafting. The applicability 
of the studies is further limited because of methods used, such 
as enzymatic isolation, are strictly regulated in a number of 
countries and principalities, including the United States (89).
Concerns have also been raised regarding the use of ADSCs 
in the form of CAL for breast augmentation following breast 
cancer therapy. Although the American Society of Plastic 
Surgeons has come to the conclusion that fat grafting does 
not increase the risk of breast cancer recurrence (90), studies 
have demonstrated that ADSCs may enhance the growth of 
proliferating cells (91-94). By contrast, no serious adverse 
event, including malignant transformation, has been reported 
following MSC treatment. However, since there remains 
little evidence regarding CAL therapy for breast augmenta-
tion post-mastectomy, it is currently recommended that 
CAL therapy should be delayed for reconstructive purposes 
in breast cancer treatment until the patient has been disease 
free for 7 years (94). Therefore producing low cost, minimally 
manipulated cells that may be used safely in the operating 
room soon after harvesting and cell isolation remains a great 
challenge in regenerative medical technology.
9. Conclusion
Preclinical studies and early clinical trials indicate that fat 
grafting enriched with SVF or ex vivo expanded ADSCs signif-
icantly increase residual graft volume. The beneficial effect of 
ASDCs on graft survival is potentially due to improved early 
vascularisation; promoted either by ASDC differentiation into 
endothelial cells or by a paracrine induced effect, although 
the exact mechanism of stem cell function remains unknown 
and requires further investigation. Although methods for 
tissue preparation, cell isolation and cell culture in CAL 
have been previously described (25,30,52,70), there remains 
a lack of consensus and no delineated ideal methodology for 
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this technique. Thus, it is critical to determine the optimal 
cell population (SVF or expanded ex vivo ADSCs) and cell 
load for human use in order to standardize this technique. A 
number of questions, including the long-term safety of CAL 
regarding previous cancer diagnosis and treatment, remain 
unanswered and long-term and larger studies are required to 
confirm previously documented favourable results and answer 
the remaining questions.
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